Email Updates

Search form

You are here


Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. TDF/FTC is approved for use as oral PrEP in a handful of countries but, for maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

There’s no question that a simple regimen of a single daily pill can slash HIV infections in people at risk. But although millions of people around the world could benefit, only 200,000 are prescribed PrEP, and 75 percent of them are in the United States. The disparity was the focus of anguished discussions this week at the largest annual US HIV/AIDS conference.

March 9, 2018
Science Magazine

Korea Bizwire reports South Korea's move to make PrEP available. Its Ministry of Food and Drug Safety approved the sale of Truvada for prevention. The article also covers continuing questions about the cost of PrEP.

February 20, 2018
Korea Bizwire

The February issue of The Journal of the International AIDS Society includes a study titled; Exploring acceptability of oral PrEP prior to Implementation among female sex workers in South Africa. In focus group discussion, 69 participants expressed their interest in PrEP and identified issues that will facilitate acceptance of this intervention.

February 1, 2018
Journal of the International AIDS Society
Subscribe to RSS - PrEP